相似文献
1
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1075-81. doi: 10.1093/infdis/jir349.
2
Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
J Virol. 2018 Jan 17;92(3). doi: 10.1128/JVI.01190-17. Print 2018 Feb 1.
3
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.
4
Prospects for immunisation against Marburg and Ebola viruses.
Rev Med Virol. 2010 Nov;20(6):344-57. doi: 10.1002/rmv.661.
5
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
PLoS Negl Trop Dis. 2012;6(3):e1567. doi: 10.1371/journal.pntd.0001567. Epub 2012 Mar 20.
6
Progress in filovirus vaccine development: evaluating the potential for clinical use.
Expert Rev Vaccines. 2011 Jan;10(1):63-77. doi: 10.1586/erv.10.152.
7
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600. eCollection 2013.
8
Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
Front Immunol. 2021 Aug 18;12:703986. doi: 10.3389/fimmu.2021.703986. eCollection 2021.
9
A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses.
Viruses. 2020 Aug 22;12(9):923. doi: 10.3390/v12090923.
10
Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.
Hum Vaccin Immunother. 2019;15(10):2359-2377. doi: 10.1080/21645515.2019.1651140. Epub 2019 Oct 7.
引用本文的文献
1
The Functional DPP4 Receptor Is an Indispensable Factor Mediating the Immune Performance of Mucosal Vaccines for Middle East Respiratory Syndrome.
Transbound Emerg Dis. 2025 Jun 10;2025:2303502. doi: 10.1155/tbed/2303502. eCollection 2025.
2
Marburg Virus Disease: Pathophysiology, Diagnostic Challenges, and Global Health Preparedness Strategies.
Ann Glob Health. 2025 Jun 2;91(1):24. doi: 10.5334/aogh.4671. eCollection 2025.
3
Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease.
Pathogens. 2025 Mar 27;14(4):322. doi: 10.3390/pathogens14040322.
4
A meta-analysis on the effectiveness of serotype O foot-and-mouth disease vaccines.
Sci Rep. 2025 May 2;15(1):15381. doi: 10.1038/s41598-025-99518-3.
5
[Platform technologies in vaccine development].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Apr;68(4):368-377. doi: 10.1007/s00103-025-04024-6. Epub 2025 Mar 4.
6
Recombinant VSVs: A Promising Tool for Virotherapy.
Acta Naturae. 2024 Oct-Dec;16(4):4-14. doi: 10.32607/actanaturae.27501.
7
Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus.
Vaccines (Basel). 2024 Dec 12;12(12):1403. doi: 10.3390/vaccines12121403.
8
Automated, Quantitative Capillary Western Blots to Analyze Host Cell Proteins in COVID-19 Vaccine Produced in Vero Cell Line.
Vaccines (Basel). 2024 Dec 5;12(12):1373. doi: 10.3390/vaccines12121373.
9
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.
PLoS Pathog. 2024 Sep 11;20(9):e1012522. doi: 10.1371/journal.ppat.1012522. eCollection 2024 Sep.
10
Abortive and productive infection of CNS cell types following in vivo delivery of VSV.
Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2406421121. doi: 10.1073/pnas.2406421121. Epub 2024 Aug 19.
本文引用的文献
1
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.
J Infect Dis. 2011 Nov;204 Suppl 3:S785-90. doi: 10.1093/infdis/jir298.
2
Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.
J Virol. 2010 Oct;84(19):10386-94. doi: 10.1128/JVI.00594-10. Epub 2010 Jul 21.
3
Postexposure treatment of Marburg virus infection.
Emerg Infect Dis. 2010 Jul;16(7):1119-22. doi: 10.3201/eid1607.100159.
4
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.
PLoS Pathog. 2010 May 20;6(5):e1000904. doi: 10.1371/journal.ppat.1000904.
5
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.
Clin Vaccine Immunol. 2010 Apr;17(4):572-81. doi: 10.1128/CVI.00467-09. Epub 2010 Feb 24.
6
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.
PLoS One. 2009;4(5):e5547. doi: 10.1371/journal.pone.0005547. Epub 2009 May 14.
7
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.
8
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.
PLoS Pathog. 2008 Nov;4(11):e1000225. doi: 10.1371/journal.ppat.1000225. Epub 2008 Nov 28.
9
Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda.
PLoS Pathog. 2008 Nov;4(11):e1000212. doi: 10.1371/journal.ppat.1000212. Epub 2008 Nov 21.
10
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
Vaccine. 2008 Dec 9;26(52):6894-900. doi: 10.1016/j.vaccine.2008.09.082. Epub 2008 Oct 18.
Zotero 插件